Autologous engineered T cell receptor therapy in advanced cancer

Autologous engineered T cell receptor therapy in advanced cancer

ABSTRACTTo overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and/or MMP1 underwe...

Descripció completa

Dades bibliogràfiques
Autors principals: Apostolia M. Tsimberidou, Mehmet A. Baysal, Abhijit Chakraborty, Borje S. Andersson
Format: Article
Idioma:English
Publicat: Taylor & Francis Group 2023-12-01
Col·lecció:Human Vaccines & Immunotherapeutics
Matèries:
Multitargeted autologous T-cell therapy
lymphodepletion
advanced cancer
adoptive cell therapy
ACT
T- cell nfusion
Accés en línia:https://www.tandfonline.com/doi/10.1080/21645515.2023.2290356

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2023.2290356

Ítems similars